Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18474182 | 0.78 | — | — | |
| SCHEMBL18474058 | 0.78 | — | — | |
| SCHEMBL17402478 | 0.77 | NOS1 (0.40) | ALDH1A1TSHR | |
| SCHEMBL17395740 | 0.77 | NOS1 (0.40) | ALDH1A1TSHR | |
| SCHEMBL6187224 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL18474063 | 0.74 | — | — | |
| SCHEMBL6183770 | 0.74 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL18474066 | 0.73 | — | — | |
| SCHEMBL18475261 | 0.70 | MEN1 (0.34) | — | |
| SCHEMBL20468135 | 0.68 | ALDH1A1 (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084783-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated with an accumulation of misfolded proteins | INFLECTIS BIOSCIENCE (FR) | 2021-08-10 | — | — | US | disclosed |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | INFLECTIS BIOSCIENCE (FR) | 2020-06-09 | — | — | US | disclosed |
| US-20200102269-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH AN ACCUMULATION OF MISFOLDED PROTEINS | INFLECTIS BIOSCIENCE (FR) | 2020-04-02 | — | — | US | disclosed |
| US-10544093-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | INFLECTIS BIOSCIENCE (FR) | 2020-01-28 | — | — | US | disclosed |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | INFLECTIS BIOSCIENCE (FR) | 2018-08-09 | — | — | US | disclosed |
| US-20170152220-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | INFLECTIS BIOSCIENCE (FR) | 2017-06-01 | — | — | US | disclosed |
| WO-2017021216-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT. | INFLECTIS BIOSCIENCE (FR) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152220-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | HSPA5, PRNP, MAPT | ALDH1A1 2576/4885TSHR 3782/4885THRB 2162/4885 |
| US-20200102269-A1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH AN ACCUMULATION OF MISFOLDED PROTEINS | HSPA5, PRNP, TBCA | ALDH1A1 2534/4885TSHR 3643/4885THRB 2038/4885 |
| US-10544093-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins | HSPA5, PRNP, MAPT | ALDH1A1 2576/4885TSHR 3782/4885THRB 2162/4885 |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | MGMT, GLI1, CA9 | ALDH1A1 148/4885TSHR 2145/4885THRB 3386/4885 |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | MGMT, GLI1, CA9 | ALDH1A1 148/4885TSHR 2145/4885THRB 3386/4885 |
| US-11084783-B2 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated with an accumulation of misfolded proteins | HSPA5, PRNP, TBCA | ALDH1A1 2534/4885TSHR 3643/4885THRB 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.